FDA Panel Endorses Pfizer Vaccine For Emergency Use

Pfizer

The Food and Drug Administration advisory committee has voted 17 to 4 in favor of granting emergency use authorization to Pfizer’s coronavirus vaccine for Covid-19 in the United States.

This means health workers and other individuals on the priority list could start receiving the first jab of the two-dose vaccine within days.

The Pfizer and BioNTech vaccine will roll out 6.4 million doses as early as Friday.

The Vaccines and Related Biological Products Advisory Committee convened on Thursday. The meeting to consider the emergency use authorization request (EUA) for Pfizer and BioNTech’s Covid-19 vaccine deliberated on the safety of the vaccine in people aged 16 years and older.

Marion Gruber, director of the Office of Vaccines Research and Review at the FDA said, “We will take what we have heard today into consideration when deciding not only the EUA issuance here but also how to move forward on the end licensure of this product.” 

The vaccine advisory committee will consider another EUA for the Covid-19 vaccine developed by Moderna.

After the endorsement, the FDA must issue a formal EUA. This could happen as soon as Friday for the Pfizer vaccine.